pharmaphorum25m
Australia joins EU in turning down Alzheimer's drug Leqembi
The regulator joins the EU regulator in refusing to register Leqembi, which gave similar reasons for its position on the drug ...
Eisai will request reconsideration of initial decision for lecanemab in Australia
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of ...
Survey: Most older Americans don't trust AI-generated health info
Most Americans 50 and older don't place much trust in health advice generated by artificial intelligence, a new survey finds.
More kids having seizures after ingesting medications, illicit drugs
The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in ...
State Street Corp's Strategic Acquisition of Biogen Inc Shares
On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 250,487 shares ...
Experts label TGA’s decision to not register Alzheimer’s drug ‘extremely disappointing’
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
Biogen (BIIB): Pioneering CNS Treatments and Future Growth Prospects
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...
pharmaphorum1h
First human skin atlas points way to healing without scars
The human skin map – which has been published in the journal Nature and is freely available here – is just one facet of the ...
JCN Newswire2h
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
Eisai will request a reconsideration of this decision under Section 60* of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in Australia.